Development and validation of risk stratification and shared decision-making tool for catheter ablation for atrial fibrillation in patients with heart failure: a multicentre cohort studyResearch in context

Bibliographic Details
Title: Development and validation of risk stratification and shared decision-making tool for catheter ablation for atrial fibrillation in patients with heart failure: a multicentre cohort studyResearch in context
Authors: Xiaodong Peng, Liu He, Jue Wang, Nan Li, Jing Cui, Shijun Xia, Song Zuo, Chao Jiang, Jinzhu Hu, Kui Hong, Zhuheng Li, Peng Zhang, Ning Zhou, Caihua Sang, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma
Source: EClinicalMedicine, Vol 83, Iss , Pp 103219- (2025)
Publisher Information: Elsevier, 2025.
Publication Year: 2025
Collection: LCC:Medicine (General)
Subject Terms: Atrial fibrillation, Heart failure, Machine learning, Clustering, Risk stratification, Radiofrequency catheter ablation, Medicine (General), R5-920
More Details: Summary: Background: The coexistence of atrial fibrillation (AF) and heart failure (HF) presents a significant challenge in risk evaluation and treatment decision-making. This study aimed to develop a shared decision-making tool that aids in risk stratification and guides radiofrequency catheter ablation (RFCA) decisions for patients with AF and HF. Methods: In this multicentre cohort study, we derived a shared decision-making tool by applying unsupervised clustering and supervised learning models to data from the China-AF registry, collected from 31 hospitals between August 1, 2011, and December 31, 2022. External validation was performed using diverse ethnic populations from the international, multicenter, randomized, open-label CABANA trial. The study included patients with AF and HF and excluded the asymptomatic patients. Association of RFCA with prognostic outcomes were assessed and compared across model-identified risk strata, focusing on composite events (cardiovascular death and stroke), all-cause death, cardiovascular hospitalization, major bleeding, and AF recurrence. This study is registered with the Chinese Clinical Trial Registry, ChiCTR–OCH–13003729. Findings: Among 3122 patients in the derivation cohort (1476 females [47.3%] and 1646 males [52.7%]) and the 778 patients in the validation cohort (345 females [44.3%] and 433 males [55.7%]), the tool identified three clusters based on 25 readily accessible clinical features. Incidence rates (per 100 person-years) of composite events were highest in cluster 1 [7.7 (95% CI, 6.9–8.6)], followed by cluster 2 [6.8 (95% CI, 6.1–7.7)], and lowest in cluster 3 [3.8 (95% CI, 3.4–4.4)] (log-rank P
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2589-5370
Relation: http://www.sciencedirect.com/science/article/pii/S2589537025001518; https://doaj.org/toc/2589-5370
DOI: 10.1016/j.eclinm.2025.103219
Access URL: https://doaj.org/article/ff1efa3d6e7e4a539c8f8fcd01d7189b
Accession Number: edsdoj.ff1efa3d6e7e4a539c8f8fcd01d7189b
Database: Directory of Open Access Journals
More Details
ISSN:25895370
DOI:10.1016/j.eclinm.2025.103219
Published in:EClinicalMedicine
Language:English